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Abstract
Background: The application of physiologically based pharmacokinetic models (PBPK) to human
studies has been limited by the lack of the detailed organ information that is required for this
analysis. PKQuest is a new generic PBPK that is designed to avoid this problem by using a set of
"standard human" default parameters that are applicable to most solutes.
Results: PKQuest is used to model the human pharmacokinetics of the volatile solutes. A
"standard human" value for the lipid content of the blood and each organ (klip) was chosen. This
set of klip and the oil/water partition coefficient then specifies the organ/blood partition for each
organ. Using this approach, the pharmacokinetics of inert volatile solute is completely specified by
just 2 parameters: the water/air and oil/water partition coefficients. The model predictions of
PKQuest were in good agreement with the experimental data for the inert solutes enflurane and
nitrous oxide and the metabolized solutes halothane and toluene.
Methods: The experimental data that was modeled was taken from previous publications.
Conclusions: This approach greatly increases the predictive power of the PBPK. For inert volatile
solutes the pharmacokinetics are determined just from the water/air and oil/water partition
coefficient. Methoxyflurane cannot be modeled by this PBPK because the arterial and end tidal
partial pressures are not equal (as assumed in the PBPK). This inequality results from the "washin-
washout" artifact in the large airways that is established for solutes with large water/air partition
coefficients.
PKQuest and the worked examples are available on the web  [www.pkquest.com].
Background
PKQuest is a new generic "physiologically based pharma-
cokinetic model" (PBPK) [1]. A PBPK provides an ap-
proach to modeling drug distribution and metabolism
that is based on the use of a physiologically realistic mod-
el of the animal. This new PBPK has been designed to pro-
vide a rigorous mathematical treatment that takes into
consideration all the different biochemical and physio-
logical properties that a drug may have, and yet be very
simple to use. Other papers in this series have described
the application of PKQuest to propranolol, D2O, ethanol,
inulin and protein bound antibiotics [1–3]. This paper
will describe the application of PKQuest to volatile sol-
utes, with particular emphasis on anesthetics.
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The use of a PBPK to model pharmacokinetics requires de-
tailed information about the blood-tissue partition coeffi-
cient for each organ. This is the feature that has limited the
applications of PBPK to human studies since it is normally
assumed that these tissue partition coefficients must be
determined for each specific solute that is studied. The
major design philosophy behind PKQuest is to increase
the predictive power of the PBPK so that it can applied to
a large variety of solutes without the need for this specific
information. This is accomplished by preprogramming a
"standard human" data set that contains most of the in-
formation that is required to model the different solutes.
The new approach for the volatile solutes that is devel-
oped in this paper is to assume that the tissue partition of
these solutes is determined entirely by a) the oil/water
partition coefficient and b) the fraction of lipid in the
blood and each organ i (klip [i]). A set of "standard hu-
man" values for klip [i] is assigned for each organ. Using
this assumption, the pharmacokinetics of any inert vola-
tile solute is completely determined (as a first approxima-
tion) by just 2 parameters: the water/air (Kwair) and oil/
water (Kfwat) partition coefficients. This allows PKQuest
to be used to predict the pharmacokinetics of any inert
volatile solute for which experimental values for these
simple physical chemical parameters are available. If the
solute is metabolized (as is the case for halothane and tol-
uene) then additional adjustable parameters (e.g., meta-
bolic liver Km and Vmax) must be added.
As a test of this approach to modeling volatile solutes,
PKQuest was applied to the simultaneous uptake and
washout measurements of Munson et al. [4] and Carpen-
ter et al. [5] for N2O, enflurane, halothane, and methoxy-
flurane. Application of PKQuest to these simultaneous
anesthetic measurements provides a stringent test of the
PKQuest assumptions because only the specific partition
coefficients (Kbair, etc) vary for the different gases while
all the other parameters (e.g. percent body fat, klip, fat
blood flow, ventilation, etc.) must be identical. In addi-
tion, using the same set of parameters to fit the roughly 20
fold difference in concentration between the Munson et
al. and Carpenter et al. data provides another test. Finally,
to show that the validity of this approach extended be-
yond the anesthetics, it was also applied to toluene, a vol-
atile solute for which detailed human PBPKs are already
available. Since the value of the oil/water partition coeffi-
cient varies from 3 for nitrous oxide to 120 for toluene,
the ability of PKQuest to model these different solutes us-
ing a single set of organ fat fractions (klip) demonstrates
the generality of this approach.
Anesthesiologists have used physiological models incor-
porating air/water partition coefficients and volumes of
distribution to predict the kinetics for more than a 150
years [6]. However, there have been only a few applica-
tions of detailed, organ specific PBPK to anesthetics. Ma-
pleson and colleagues developed a detailed anesthetic
PBPK [7–9] and measured the relevant PBPK parameters
[10–12]. Smith and colleagues [13,14] and Fukui and
Smith [15,16] have developed complex PBPKs in which
the anesthetic interacts with and modifies the organ pa-
rameters. The primary application of these models has
been to illustrate the theoretical importance of the differ-
ent model components. The only detailed attempts to fit
human data with a PBPK are for nitrous oxide in man [17]
and halothane in infants [18]. Allott, Steward and Maple-
son [19] also fit a PBPK to the experimental data for ha-
lothane in the dog. Both of these halothane studies were
incomplete because they did not account for metabolism.
The most complete PBPK for halothane is the rat study of
Loizou et al. [20] which includes a metabolic component
that is saturable and inactivates. There have been no pre-
vious attempts to use a PBPK to model multiple, simulta-
neously measured anesthetics such as is described in this
paper.
In contrast to the PBPK model of Mapleson [7], PKQuest
does not model the vascular time delays and therefore is
not applicable to short time kinetics (less than a minute).
However, PKQuest does incorporate a number of features
that are not present in Mapleson's model, including tissue
metabolism, capillary limitation (either in the lung or tis-
sue) and ventilation-perfusion mismatch.
The PKQuest program and all the examples used here are
freely available on the WEB at  [www.pkquest.com]. The
reader is encouraged to download these routines and try
them out.
Methods
PBPK program and its assumptions
PKQuest [1] was used for all the analysis in this paper. All
the figures shown in this paper are direct copies (in jpeg
format) of standard PKQuest output. PKQuest makes sev-
eral simplifying assumptions (see [1]). It is assumed that
each organ can be modeled as a single well-stirred com-
partment. For the volatile solutes studied here, it is also as-
sumed that the blood-tissue exchange is flow limited so
that the partial pressure in the tissue is equal to that in the
vein leaving the tissue. This is clearly an approximation
and effects such a diffusion gradients, countercurrent ex-
change and heterogeneous organ blood flows [21–23]
will produce small deviations from this assumption. It is
also assumed that the influence of the anesthesia in the
Carpenter et al. studies on the PBPK parameters can be ne-
glected [14,24]. Although these solutes may consist of
stereo enantiomers, it is assumed that there is no signifi-
cant difference in the pharmacokinetics of the enantiom-
ers, which is supported by experiment [25,26]. It isBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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Figure 1
Comparison of PKQuest model alveolar gas concentration (line) and experimental data (squares) for the end tidal concentra-
tion (volume %) during uptake and washout of enflurane. The figures in the left hand column are for the data of Carpenter et
al. [28] (inspired concentration = 0.518%) and those in the right hand column are for data of Munson et al. [4] (inspired con-
centration = 0.0186%). The figures in the second row are for the uptake in the form of a semi log plot of the difference
between the inhaled concentration (which would correspond to the long time equilibrium concentration) and the end expired
concentration as a function of time. The figures in the third row are a semi log plot of the end expired concentration as a func-
tion of time. The data are the mean values for 9 (Carpenter et al) and 6 (Munson et al.) subjects.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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assumed that the metabolism of N2O and enflurane is
negligible [24,27,28], and that the loss through the skin
can be neglected [29].
The free water concentration (Cfree) plays a central role in
the PKQuest calculations (see [1] for details). For the
blood or any organ, the free concentration can be related
to the total (measured) concentration (Ctot) by the rela-
tion Ctot = Cfreewfract/fw where wfract is the water frac-
tion in the organ and fw is the fraction of the solute that
is free in the water phase. The parameter fw [i], the frac-
tion free in organ i (including vascular compartments),
characterizes the fraction free (and bound) and the corre-
sponding tissue/blood partition coefficients. In general,
this parameter must be experimentally determined for
each solute (and organ). However, for these volatile sol-
utes it is assumed that the "bound" solute is equal to the
solute dissolved in the blood or tissue lipid. For this case,
the parameter fw [i] is completely determined by Kfwat
(oil/water partition coefficient) and klip[i] (the fraction of
lipid in each organ):
fw[i] = wfract[i]/(wfract[i] + Kfwat*klip[i])
Although PKQuest uses only Kwair (water/air partition),
Kfwat and klip[i] for the actual calculations, a variety of
combinations of Kfwat, Kwair, Kbair (blood/air parti-
tion), Kbwat (blood/water partition), etc. can be entered.
For example, for the anesthetics investigated here, the 3
parameters Kbair, Kwair and Kfwat are known experimen-
tally and are entered. PKQuest then uses these 3 parame-
ters to calculate the corresponding value for klip [blood]
and replaces the default "standard human" value by this
experimental value.
Experimental pharmacokinetic data
The experimental data was obtained from previous publi-
cations. The anesthetic data was based on the results in the
papers by Carpenter et al. [5] and Munson et al. [4]. Both
of these studies determined the simultaneous uptake and
washout of nitrous oxide (N2O), enflurane, halothane,
and methoxyflurane. Munson et al. used low, sub-anes-
thetic concentrations of all 4 gases with a total inhaled
concentration of about 2% so that the second gas effect
[30] was negligible. Carpenter et al. first induced anesthe-
sia with high (65–70%) concentrations of N2O and then,
after the N2O had equilibrated, added the other 3 gases at
concentrations about 20 times higher than that of Mun-
son et al. (at a total inhaled concentration of less than 2%)
and then washed them out while maintaining constant
N2O levels. Thus, the second gas effect can also be neglect-
ed for the data of Carpenter et al. for enflurane, halothane,
and methoxyflurane (but not N2O). The experimental
data points were obtained by using UN-SCAN-IT (Silk Sci-
entific Corporation) to read the data from the published
figures (figs. 2 and 3, Munson et al.; figs. 1 and 2, Carpen-
ter et al.).
The Munson et al data [4] represents the mean value for 6
healthy fasted unanesthetized males breathing for 30
minutes a gas containing 0.0069 % methoxyflurane;
0.0136 % halothane; 0.0186 % enflurane; and 1.88%
N2O. The Carpenter et al. data [5] represents the mean
values for 4 male and 5 female healthy subjects undergo-
ing donor nephrectomy. The subjects were administered
65–70% N2O for 30 minutes and then a mixture of
0.348% isoflurane, 0.518 % enflurane, 0.226 halothane
and 0.0469 % methoxyflurane was administered for 2
hours. After discontinuing these gases, anesthesia was
maintained with fentanyl, thiopental and N2O for the du-
ration of the operation. The Carpenter et al. washout data
was collected at intervals during the first day, and once a
day for the next 5 to 8 days. Since subjects became ambu-
latory upon recovering from surgery with the associated
changes in PBPK parameters (eg. muscle blood flow, ven-
tilation) only data out to 15 hours was used. In fitting this
data it is assumed that using the mean values of the con-
centration versus time averaged over a population is
equivalent to treating these values as representative of a
single "average" person [31]. For this data with its relative-
ly small standard error (typically ± 2 to 3 % of the inspired
concentration), this should be a reasonably accurate as-
sumption.
The toluene data was based on the published investiga-
tion of Pierce et al.[32]. Pierce et al. [32] exposed 26 male
Caucasian subjects to 50 ppm each of 1H8-toluene and
2H8-toluene for two hours at rest, and collected venous
blood and alveolar breath samples for up to 120 hours.
Their subject-specific PBPK explained 91% of the ob-
served data variability and found interindividual toxicok-
inetic differences. All the data for each individual in this
series was generously provided by C.H. Pierce. Two differ-
ent individuals in the Pierce et al. series were chosen to be
modeled by PKQuest. The two subjects (subjects 5a and
15 in Table I of Pierce et al.) were chosen because they had
large differences in percent fat content (38% versus 22%)
and corresponding differences in toluene kinetics.
Experimental partition coefficients
The partition coefficients were based on previous pub-
lished data. The values of Kwair for the anesthetics (enflu-
rane 0.7; halothane 0.8; N2O 0.47; methoxyflurane 4.33)
were from the review by Steward et al. [10]. The average
values of blood/air partition coefficient for the Munson et
al subjects ([4], Table II) were used for the anesthetics (en-
flurane 2.0; halothane 2.32; N2O 0.418; methoxyflurane
13.9). The value of Kfwat was obtained from different
sources (enflurane 130 [10], N2O 2.97 [10], halothane
170 [33], methoxyflurane 208 [34]) Identical values wereBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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used for modeling the Munson et al. and Carpenter et al.
data.
For the toluene data, the value of the blood/air partition
coefficient was measured for each of the two subjects that
were modeled (Table I, [32]). The value of the lipid/air
partition coefficient was based on the average value re-
ported by Pierce et al. [35].
Standard Human parameters
The default standard values are stored as a Maple proce-
dure in PKQuest. The values used for organ flows, vol-
umes, etc. are identical to those used in all the other
applications of PKQuest [1–3]. A list of some of the pa-
rameters is included in additional file 1. For a complete
listing, see the routine on the web site
[www.pkquest.com].
The critical new parameter set required for this applica-
tion is the value of klip [i], the fraction of lipid in each or-
gan i. This parameter (along with Kfwat) determines the
tissue/water partition. This parameter set was determined
by finding values of klip that would reproduce the tissue/
air partition coefficients reported by Zhou et [33] for a
number of anesthetic solutes for human heart, brain, liv-
er, muscle and fat and assuming that the other organs
(skin, intestine, kidney) had similar values. The values of
klip chosen for each organ are: liver 0.028; intestines 0.02;
kidney 0.028; and all other organs 0.017. The only other
parameter that was adjusted to fit the data for these sol-
utes was the fat blood flow. The PKQuest global (simulat-
ed annealing) and local (Powell) optimization routines
were used to select the fat blood flow that provided the
best fit to the enflurane data. This value was then used for
all the other solutes that were investigated.
PKQuest Maple input procedure
The pharmacokinetics for each of the solutes is completely
characterized by the Maple input procedure for that sol-
ute. The complete procedures are available on the web (
[www.pkquest.com]). A slightly abbreviated listing of the
procedures for each of the solutes used in this paper is in-
cluded in additional file 1.
Results
Enfluane
As described previously [1], each compound modeled by
PKQuest is completely characterized by a short Maple (
[www.maplesoft.com]) procedure that lists the PKQuest
parameters that are unique for that solute. The Maple pro-
cedure for enflurane for the data of Carpenter et al. [5] is
listed here:
enflurane:=proc()
Figure 2
Comparison of model alveolar gas concentration (line) and
experimental data for the end tidal concentration (volume %)
during uptake and washout of nitrous oxide (inhaled concen-
tration = 1.88%). The figures in the 3 rows are similar to
those in fig. 1.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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Figure 3
Comparison of model alveolar gas concentration (line) and experimental data for the end tidal concentration (volume %) dur-
ing uptake and washout of halothane. The left column is for the data of carpenter et al. [28] (inspired concentration = 0.226%)
and the right column is for the data of Munson et al. [4] (inspired concentration = 0.0135%). The figures in the 3 rows are sim-
ilar to those in fig. 1.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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defaultpar():
Wtot:=70.0; #Body weight
standardhuman(Wtot);
Fat:=0.25; #average value for men and women
cunit:="10 ml";
Kbair:=2.0;# blood/air partition coefficient – value for
Munson fasted subjects.
Kwair:=0.75;#water/air partition coefficient – standard
reference value
Kfair:=98;#fat/air partition coefficient – literature value
Kfwat:=Kfair/Kwair;
ninput:=1; finput[1]:=table([organ=lung, type=1,
rate=0.518, tbeg=0,
tend=120, csteady=0, padjust=0]);#2 hour constant
lung input
The body weight was set arbitrarily to the standard value
of 70 Kg since the input dose should scale with body
weight through the alveolar ventilation parameter. The
fraction body fat (= Fat) was chosen based on the standard
literature average value [36] for the 4 men and 5 women
studied by Carpenter et al. Since PKQuest always uses
units of liters, minutes and Kg, the concentration of ml an-
esthetic/100 ml total volume (abbreviated as %) used by
Carpenter et al. corresponds to a "cunit" of 10 ml per liter
(this parameter is only used for display of output and does
not directly enter the calculations). The value of Kbair is
the average value reported by Munson et al. [4] for the
fasting subjects. The value of Kwair is from the standard
reference [10] and Kfair is based on measurements of sol-
ubility in olive oil [10] and in human fat tissue [33]. The
input was a constant 120 minute inhaled concentration of
0.518%. Note that all the parameters required to charac-
terize enflurane are direct experimental measurements so
that there are no adjustable parameters (see Discussion
Section for further discussion of this point).
It should be emphasized that the above short procedure
completely characterizes the enflurane PBPK. All the other
parameters are determined by the default values set by the
calls to defaultpar() and standardhuman(). (The user can
override the default values and input an arbitrary value for
any parameter.). The partition coefficients for the individ-
ual organs are determined by the default value for the frac-
tion of lipid in each organ i (klip[i]).
The PKQuest output using this "enflurane" input proce-
dure is shown in the left hand column of fig 1 along with
the experimental data (squares) of Carpenter et al. [5]. The
top figure shows the results during uptake and washout
and the figures in the second and third rows show the
semi log plots of the uptake and washout, respectively. All
the figures shown in this paper are copied directly from
the standard PKQuest output.
The corresponding plot for the enflurane data of Munson
et al. [4] is shown in the right hand column of fig. 1. Ex-
actly the same set of parameters were used except that: 1)
the fraction of body fat was reduced to 0.16, the standard
literature average value [36] for the 12 young male sub-
jects used in this study; and 2) the experimental inhaled
enflurane concentration was 0.0186 % for 30 minutes
(versus 0.518% for 120 minutes for Carpenter et al). The
fact that both sets of data can be fit using an identical pa-
rameter set, even though the concentrations differ by a
factor of 28, indicates that the enflurane pharmacokinet-
ics must be linear over a large concentration range.
Nitrous oxide
Figure 2 compares the PKQuest output with the experi-
mental data of Munson et al. [4] for N2O. (The N2O data
of Carpenter et al. could not be used because of the large
second gas effect.). The partition coefficients used for this
calculation are the standard N2O literature values:
Kwair=0.47 [10]; Kfair=1.4 [10] and Kbair=0.418 (Mun-
son et al. [4], fasting subjects). All the other parameters are
identical to those used for the Munson et al. enflurane da-
ta.. (See additional file 1 for the complete N2O Maple pro-
cedure). The agreement between the PKQuest predictions
and experiment is excellent for the N2O uptake. However,
there is a significant deviation between the predictions
and the data during the washout that is especially appar-
ent in the semi log plot. There is no obvious explanation
for this discrepancy and it may be artifactual (see Discus-
sion Section).
Halothane
There is an additional complication when modeling the
halothane data because a significant fraction of the ha-
lothane disappearance is the result of metabolism
[24,27,28,37–41]. Loizou et al. [20] developed a detailed
PBPK in the rat with the halothane metabolism described
by a 4 parameter function that included both Michaelis-
Menten and inactivation components. Although there is
qualitative evidence that halothane metabolism in hu-
mans is non-linear, saturating at higher concentrations
[27], the quantitative aspects of halothane metabolism
are poorly characterized in the human. Probably the most
relevant data is provided by investigations in miniature
swine. Sawyer et al. [38] reported that the percent liver
clearance during the halothane washout in miniatureBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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swine was 77% at an alveolar concentrations of 0.0026%
and fell to 5% at an alveolar concentration of 1%. Halsey
et al. [37] found that 35% of the halothane entering the
miniature swine liver was metabolized at a steady state al-
veolar concentration of 0.0065%.
For this study it was assumed that the halothane metabo-
lism could be described by a two parameter Michaelis-
Menten (Km and Vmax) liver component. The two pa-
rameters were adjusted to so that they a) provided a good
fit to the experimental halothane data of both Carpenter
et al. [5] (inhaled concentration of 0.226%) and Munson
et al. [4] (inhaled concentration of 0.0135%) and b) were
roughly consistent with the miniature swine data. The fi-
nal values in partial pressure units were Km = 0.01 ml/100
ml and Vmax = 0.6 ml/min for the standard 70 Kg human.
This corresponds to a water concentration for Km of 3.57
µmole/liter and a Vm of 21.4 µmole/min. This Km is sim-
ilar to the Km of 2.03 µmole/liter in the rat [20]. Given the
limited human quantitative data that is available, these
human metabolic parameters should be regarded only as
a first approximation. Figure 3 shows that this set of met-
abolic constants provided a good fit to the 17 fold range
of inhaled halothane concentrations used in the Carpen-
ter et al. (0.226 % concentration) and Munson et al.
(0.0136 % concentration) experiments. The partition co-
efficients used in these calculations were the standard lit-
erature values: Kbair = 2.32 (Munsen et al. fasted subject);
Kwair = 0.8 [10] and Kfair = 137 [33]. (See additional file
1 for the complete halothane Maple procedure). For these
parameters, the percent liver halothane clearance varied
from 48% at an alveolar concentration of 0.0002%; to
30% at a concentration of 0.07%; to 7% at a concentra-
tion of 0.26% – similar to the swine data. Using the
PKQuest PBPK results, 65% of the halothane should have
been recovered during a 5 day washout period relative to
the total uptake. This is somewhat greater than the 55%
recovery directly estimated for this same data by measur-
ing the mixed expired halothane concentration and venti-
lation rate once per day for 5 days [28]. The standard
output of PKQuest provides all the above information
(fractional liver clearance, recovery during washout, etc.).
Methoxyflurane
As shown by the results in figs. 1–3, PKQuest provides an
accurate description of the human pharmacokinetics of
the uptake and washout of enflurane and halothane and
the uptake of N2O. In contrast, the PKQuest predictions
are clearly incorrect for methoxyflurane. Figures 4 show
the PKQuest predictions for the alveolar concentration
(solid line) compared with the experimental data of Car-
penter et al. (fig 4, left column) and Monson et al. (fig. 4,
right column). (See the additional file 1 for the complete
methoxyflurane Maple procedure). The partition coeffi-
Figure 4
Comparison of model alveolar gas concentration (line) and experimental data for the end tidal concentration (volume %) dur-
ing uptake and washout of methoxyflurane. (No metabolism). Left column is data of carpenter et al. [28] (inspired concentra-
tion = 0.0469%) and right column data of Munson et al. [4] (inspired concentration = 0.0069%). The figures in the 3 rows are
similar to those in fig. 1.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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cients used for these figures are the standard literature val-
ues: Kbair = 13.9 (Munson et al. [4] fasted subjects); Kfwat
= 208 [34]; Kwair = 4.0 [42]. It can be seen that the
PKQuest concentrations during uptake are about 30% less
than the experimental values. The actual error is even
worse than this because these PKQuest predictions ignore
metabolism, which can account for as much as 70% of the
total removal [24,27,28,37,43]. Including metabolism
would increase the difference between the PKQuest and
experimental results during uptake. The explanation for
this poor fit is provided in the Discussion section.
Toluene
Some of the most comprehensive and sophisticated hu-
man PBPKs have been developed to describe the pharma-
cokinetics of volatile toxic solvents such as toluene
[32,44,45], styrene [46,47], and methyl chloride [48]. The
most involved models incorporate several different fat
and muscle compartments with different flows and allow
for changes with time in the blood flows as the subject's
exercise level varies [45,47,48]. These studies have also in-
troduced a Bayesian approach to determine the popula-
tion distribution of the PBPK parameters [45,47].
PKQuest cannot complete with these PBPKs for this class
of solutes. The only purpose of applying PKQuest to tolu-
ene is to show that the new approach developed here of
using just klip and the oil/water partition coefficient to
characterize the tissue partition is valid for a wider class of
solutes than just the anesthetics gases (at least as a first ap-
proximation). PKQuest was applied to data for two indi-
viduals (subjects 5a and 15) that were chosen from the
detailed investigations of Pierce et al.[32] because they
had large differences in percent fat content (38% versus
22%) and corresponding differences in toluene kinetics.
The Maple input procedure for subject 15 is:
toluene_15:=proc()
defaultpar():
Wtot:=86.2; #Body weight
standardhuman(Wtot);
Fat:=0.22;# Fraction of body weight that is fat for subject
15
cunit:="micromole"; # concentration in units of micro-
mole/liter
concunit[1] :2; # experimental output = whole blood
conc
ninput:=1; finput[1]:=table([organ=lung, type=1,
rate=2.0, tbeg=0,
tend=120, csteady=0, padjust=0]); #2 hour constant
input to the lung of 2 µM
Kfair:=962;# fat/air partition coefficient
Kbair:=22.2; # blood/air partition coefficient for subject
15
Kfbld:=Kfair/Kbair; #Calculated fat/blood partition co-
efficient
alvent:=6.07; # alveolar ventilation for subject 15
Tclr [liver]:=25.0;#Liver clearance optimized to provides
best fit to data
The total body weight (Wtot), body fat fraction (Fat),
blood/air partition coefficient (Kbair) and alveolar venti-
lation (alvent) were measured for each individual subject
(see Table I, Pierce et al. [32]) and these values were used
as input. The value of the lipid/air partition coefficient
(Kfair) was set equal to the average value determined by
Pierce et al. [35]. Since Kwair is not input, PKQuest esti-
mates Kwair using Kbair and Kfbld and the default fat con-
tent of blood (klip [vein]). The input function was a 2
hour inhalation of toluene at a constant gas concentration
of 2 µM. The only adjustable parameters are the metabolic
kinetic constants. The rat liver has a number of enzymes
involved in toluene metabolism [49]. Since the Km for all
of these enzymes is in the mM range, while the blood tol-
uene concentrations for this data are in the µM range, it
was assumed that the metabolism is linear which, in
PKQuest, is indicated by using Tclr (in place of Vm and
Km). The value of Tclr was obtained by using the Powell
minimization routine that is built into PKQuest to opti-
mize the fit to the blood data. Pierce et al. [32] divided the
metabolism between the liver and lung. However, since
there is little direct information about human lung metab-
olism of toluene, it was assumed here that only the liver
was involved in the metabolism.
Subject 5a was modeled using the same procedure using
the body weight (121 Kg), fat fraction (0.38) alveolar ven-
tilation, and Kbair measured for this subject. (See the ad-
ditional file 1 for the complete subject 5a Maple
procedure). The value of Tclr for subject 5a was set equal
to the Tclr of subject 15 scaled by body weight. All the oth-
er parameters were identical to those for subject 15.
Figure 5 shows the agreement between the PKQuest pre-
dictions for the arterial (black) and venous (red) blood
concentration and the experimental data for subject 5aBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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(left hand column) and 15 (right hand column) during
the time course of toluene washout. (PKQuest allows an
arbitrary number of different organ concentrations to be
simultaneously displayed). Pierce et al. sampled "arterial-
ized" venous blood. Since the PKQuest venous and arteri-
al concentrations are identical at the time points of the
experimental data (fig. 5), the distinction between artery
and vein is not significant. Figures 6 show the correspond-
ing fits for the alveolar gas concentration. It can be seen
that the agreement is quite good and the differences in the
pharmacokinetics for the two subjects can be explained by
differences in the fat fraction. It should be emphasized
that there is only one adjustable parameter for these 2
subjects – the Tclr of subject 15.
Perfusion-Ventilation Mismatch
A unique feature of PKQuest is that it provides a direct
simulation of the mismatch between perfusion and venti-
lation. A detailed description of the equations and proce-
dures used for this simulation is provided in the original
paper [1]. Briefly, the lung is divided into Nlung equal
volume compartments, with the blood flow (Q) and ven-
Figure 5
Comparison of model arterial (black) and venous (red) whole blood concentration (µM) and experimental arterialized blood
data during washout of toluene. Left column is for subject 5a, right column is for subject 15. The figures in the 3 rows are sim-
ilar to those in fig. 1.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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tilation (V) to each compartment determined by a bivari-
ate, uncorrelated, log-normal function [50];
The value of Nlung is determined by the user input pa-
rameter N1dim (Nlung = (2*N1dim)2). The two parame-
ters σ Q and σ V (the "log standard deviation") characterize
the distribution of the blood perfusion (σ Q) and the ven-
tilation (σ V) to the different compartments of the lung.
The default values of σ Q and σ V of 0.4 were determined by
applying the analysis of Wilson and Beck [50] to the ven-
tilation-perfusion ratio distribution for normal young
men [51]. The rates of perfusion and ventilation to each
lung compartment are assumed to be uncorrelated (see
[1] for details). This assumption is consistent with recent
direct measurements of regional perfusion and ventila-
tion [52,53]. Results will be shown here for the case where
the lung is divided into 16 equal volume compartments
(N1dim = 2, Nlung = 16). This provides a good test of the
importance of perfusion-ventilation mismatch. (Increas-
ing N1dim to 3, corresponding to 36 lung compartments,
changes the results by less than 2%). Using the default val-
ues of σ Q and σ V the fraction of total flow and total venti-
lation assigned to each of the 16 compartments is (flow
fraction, ventilation fraction): (.0432, .0423); (.0423,
.0549); (.0423, .0659); (.0423; .0869); (.0549, .0423);
(.0549, .0549); (.0549,.0659); (.0549, .0869); (.0659,
.0423); (.0659, .0549); (.0659, .0659); (.0659, .0869);
(.0869, .0423); (.0869, .0549); (.0869, .0659); (.0859,
.0869).
Figure 7 shows the influence of perfusion-ventilation mis-
match on the PKQuest results for the enflurane data of
Munson et al. [4]. The predicted alveolar concentration is
shown for a) the 1 compartment homogenous lung mod-
el (black); and the 16 compartment model with b) the de-
fault (normal) values for sig_v and sig_f (red); c) twice the
normal values of sig_v and sig_f (green); and d) three
times the normal values of sig_v and sig_f (blue). It can be
seen that the 16 compartment model with normal sig_v
and sig_f (red) is almost indistinguishable from the ho-
mogeneous 1 compartment model (black). Thus, normal
values of perfusion-ventilation mismatch have no signifi-
cant effect on the uptake and washout of enflurane. It is
not until the normal values of sig_v and sig_f are increased
by a factor of about 3 that differences become significant.
Although the effect of the perfusion-ventilation mismatch
is small, it can be important for some experimental meas-
urements. Figure 8 shows the alveolar (black), arterial
(red) and venous (green) N2O concentration using the 16
compartment model and the default (normal) of values of
sig_v and sig_f for the conditions of Munson et al. [4] –
with all concentrations expressed in terms of the partial
pressure gas concentration. It can be seen that the per-
fusion-ventilation mismatch produces a small difference
in the alveolar and arterial concentrations during uptake
(for the 1 compartment lung model, alveolar and arterial
concentrations would be identical). This result is in quan-
titative agreement with the experimental measurements of
Eger et al [54] in conscious subjects: At 1.5 minutes,
PKQuest Part/Palv = 0.92; experimental Part/Pendtidal =
0.92; At 8 minutes: PKQuest = 0.98 l experimental = 0.98.
Discussion and conclusions
Enflurane, nitrous oxide, halothane and toluene
The simple PKQuest approach of using a single set of
"standard human" values for the lipid fraction of each or-
gan (klip) to predict tissue/blood partition provides an ac-
curate prediction of the pharmacokinetics of these 4
volatile solute. The word "prediction" (and not "descrip-
tion") is purposely used here because most of the param-
eters are based on the default, previously determined set
of PBPK data and there is a minimum of adjustable pa-
rameters. For example, in the PKQuest input for the enflu-
rane pharmacokinetics (fig. 1) there are no adjustable
parameters. Every constant in the procedure enflurane()
listed above is pre-determined from previous measure-
ments. In this sense, the time dependence of the alveolar
enflurane concentration during washin and washout
shown in fig. 1 is a true prediction, based on previous
measurements.
This example for enflurane is slightly misleading because
the default blood flow in "standard human" was adjusted
to give the best fit to the enflurane data. The fat blood flow
parameter plays an important role in determining the ac-
curacy of the fit to the experimental data. Figure 9 com-
pares the PKQuest output for enflurane using the default
fat blood flow (0.056 liters/min/Kg; black) and twice the
default value (red). The generality of this fat blood flow
value is evidenced by the good fit that was obtained when
it was used in the modeling of the Munson et al. and Car-
penter et al. data for halothane (fig. 3) and the Pierce et al.
data for toluene (figs. 5 and 6), solutes for which the fat
blood flow has a larger influence because of the larger val-
ue of the oil/water partition coefficient.
This use of the enflurane data to determine the fat blood
flow illustrates one of the main advantages of having a
PBPK program such as PKQuest that is general enough
that it can be applied to a large variety of solutes. Since dif-
ferent solutes have different sensitivities to the different
PBPK parameters, using a variety of solutes to optimize
the parameters increases the validity of the PBPK. Other
examples of PKQuest standard human parameters that
were optimized this way are the muscle blood flow (opti-
mized using human D2O pharmacokinetics [2]) and the
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extracellular space (optimized using human inulin phar-
macokinetics [3]).
The single most important difference between PKQuest
and other PBPKs that have been applied to these solutes is
the way the tissue/blood partition coefficient is handled.
The conventional approach is to directly measure this par-
tition coefficient for each solute in various classes of tissue
in animals, and then use these values in the human mod-
el. In contrast, in PKQuest this partition coefficient is de-
termined just from the value of the oil/water partition
coefficient (along with the default value of the organ and
blood lipid content). Since this partition coefficient is a
simple physical chemical value and is usually available in
the literature, this means that one can apply PKQuest to
solutes even when no animal tissue partition data is avail-
able. The ability of this approach to describe the pharma-
cokinetics of solutes with an oil/water partition varying
from 3 (N2O) to 120 (toluene) demonstrates the large
range of its validity.
The pharmacokinetic approach that seems to be currently
favored for anesthetics is to use a general multi-compart-
ment fit rather than a PBPK [41,55]. In this approach, the
Figure 6
Comparison of model alveolar gas concentration (line) and experimental data for the end tidal concentration (µM) during
washout of toluene. Left column is for subject 5a, right column is for subject 15. The figures in the 3 rows are similar to those
in fig. 1.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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data is first fit with a multi-exponential function that is
then interpreted in terms of exchanges between a central
compartment (the vascular system) and an adjustable
number of peripheral compartments (a "mammillary"
system). Although this approach may be mathematically
similar to a PBPK, it is completely different philosophical-
ly. The advantage of the multi-compartment approach is
that it is completely general and puts no restrictions or
previous assumptions on the pharmacokinetic model.
This advantage is also its main disadvantage. For example
in a multi-compartment analysis of anesthetics by Yasuda
et al. [41] there are 10 different rate constants that are op-
timized for each different anesthetic and these constants
are then interpreted in terms of compartments and flows.
In contrast, the major design feature of PKQuest is to have
as many parameters as possible set by default based on
previously determined measurements, with the amount
of user input reduced to its absolute minimum. For the
case of the typical volatile solute described here, the user
only needs to input the water/air and oil/water partition
coefficients and the metabolic parameters. All the other
parameters required for the PBPK (organ volumes, blood
flows, alveolar ventilation, organ/blood partition and vol-
ume, etc.) are determined simply by a call to "standardhu-
man". By using all the previous information that is
available to restrict the model and minimize the number
of adjustable parameters, PKQuest greatly increases the
predictive power of the analysis.
The one exception to the generally good agreement be-
tween the PKQuest predictions and the experimental data
for these solutes is for the washout of N2O (fig. 2). Al-
though the differences between the PKQuest and experi-
mental data are small in absolute value, they represent
large relative values. For example, for the last data point
(60 minutes), the PKQuest prediction for the end expired
gas concentration is 0.067% while the experimental value
is 0.026% (for an inhaled concentration of 1.88%). (This
difference is larger than the standard error of the last data
point.) This difference may be artifactual. For example,
the experimental N2O data (fig. 2) has a marked differ-
ence in the degree of equilibrium reached during uptake
(93%) versus washout (98.7%). This result is not expected
theoretically and is not consistent with the detailed exper-
imental results of Salamitre et al. [56] who found approx-
imately equal equilibration times during uptake and
washout of sub anesthetic doses of N2O. Another indica-
tion of the problem presented by this discrepancy is that
it was not possible to significantly improve the fit by ad-
justing any or all of the PKQuest parameters. Any param-
eter change that improved the fit for the washout,
significantly worsened the fit for the uptake and the addi-
tion of a perfusion-ventilation mismatch did not improve
the fit. One possible explanation is a small error in the
quantitative measurements (made in 1977) of Munsen et
al [4] at low N2O concentrations. Other possibilities are a
difference in some physiological parameters (e.g. ventila-
tion) during uptake and washout or an error in reading
the data off the published linear plot.
Figure 7
Effect of perfusion-ventilation mismatch on the model alveo-
lar enflurane concentration: black: 1 compartment homoge-
neous model; red: 16 compartment model with default
(normal) values of log standard deviation of flow and ventila-
tion; green: 2 times normal values of log standard deviation;
blue: 3 times normal values of log standard deviation.
Figure 8
Effect of perfusion-ventilation mismatch on the model alveo-
lar (black), arterial (red) and venous (green) partial pressure
for nitrous oxide uptake and washout. Sixteen compartment
lung model with default log standard deviations of perfusion
and ventilation.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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Methoxyflurane
Methoxyflurane is a notable exception to the generally
good agreement between the PKQuest PBPK and the ex-
perimental data. For methoxyflurane, the experimental
end tidal partial pressure (squares, fig. 4) is about 30%
greater than the PKQuest prediction during uptake (line,
fig. 4). It is assumed in the PBPK model that the arterial
blood and alveolar gas partial pressures are equal and cor-
respond to the experimentally measured end tidal gas par-
tial pressure. Thus the error in fig. 4 is equivalent to the
statement that "the arterial partial pressure is significantly
less than the end tidal partial pressure". This discrepancy
for methoxyflurane had been noted previously in the old-
er literature. Holaday et al. [57] reported that during
methoxyflurane uptake, the arterial partial pressure was
only about 50% of the end expired value. Similarly,
Stoelting [58] observed that at the end of the methoxyflu-
rane uptake, the arterial partial pressure was 60% of the
end expired, while during washout, the two values were
nearly identical. Despite these clear indications that there
was something anomalous about methoxyflurane, this
problem seems to have been generally ignored in the re-
cent literature.
This inequality is almost certainly caused by the classic
"washin-washout" artifact that has been described for gas-
es with large blood/air partition (Kbair) coefficients
[47,59–65]. This artifact is created when, during inspira-
tion, the high concentration gas dissolves in the tissues of
the bronchial tree, and then, during expiration, moves
back into the air, raising the end tidal concentration above
the alveolar values. For extremely soluble solutes such as
ethanol (Kbair = 1756), the expired gas concentration is
dominated by exchange with the conducting airway and is
almost independent of the alveolar concentration [63,65].
For gases of intermediate solubility, such as styrene (Kbair
= 48) or toluene (Kbair = 18) the effect is less dramatic
and has often been overlooked. This analysis provides a
good example of the advantage of a PBPK such as PKQuest
over the more general compartmental (mamillary) mod-
el. It is obvious from the PKQuest analysis (see fig. 4) that
some model assumption must be wrong. In contrast, in a
detailed compartmental (mammillary) model analysis of
the simultaneous uptake and washout of methoxyflurane
and other gases it was recognized that methoxyflurane
was different, but the "reason for this discrepancy is not
clear" [66].
The strongest evidence supporting this explanation for the
discrepancy in the methoxyflurane data is provided by a
comparison with toluene. Since the blood/air partition
coefficients are similar for toluene (Kbair = 18) and meth-
oxyflurane (Kbair = 13.9), this artifact should be of similar
magnitude for these two solutes. During the uptake of tol-
uene in resting subjects, the end tidal partial pressure is
only about 1/2 the arterial value [67], similar to what is
observed for methoxyflurane ([57,68], and see fig. 4).
However, when these same subjects begin to exercise, in-
creasing the ventilatory rate by a factor of 2.5, the arterial
and end tidal gas concentrations become approximately
equal [67]. Presumably, at the higher rates of ventilation,
there is relatively less time for exchange with the airways,
and the artifact decreases. This suggests that solutes such
as methoxyflurane or toluene are right on the boundary of
where this artifact becomes important. The artifact be-
comes negligible for halothane with a Kbair of 2.2 as indi-
cated by the nearly identical end tidal and arterial partial
pressures [58], and the good agreement between the
PKQuest results and the experimental data (see fig. 3).
For solutes such as toluene [45,67], styrene [47] and
methoxyflurane [58] there is, at first glance, a peculiar
asymmetry in the data that has caused some confusion:
during uptake there is a large difference in the end tidal
and arterial partial pressures, while, during washout, there
is only a small or negligible difference. However, this
asymmetry disappears if the data is reexamined as follows:
For the resting toluene data of Carlsson et al. [67] during
uptake the inspired concentration is 300 mg/m3, the end
tidal concentration is 72 mg/m3, and the arterial concen-
tration is 585 mg/m3. Assuming a Kbair of 18, this arterial
concentration corresponds to a gas concentration of 32
mg/m3, an end tidal – arterial difference of 55%. If the ar-
tifact were not present and the end tidal equaled the arte-
rial, then the end tidal concentration should have been 32
mg/m3. Thus, the net rate of gas uptake (inspired – end
tidal) is decreased about 13% (= (72–32)/300) by the ar-
tifact. If a symmetrical error was present during washout,
Figure 9
Effect of fat blood flow on model alveolar enflurane concen-
tration (volume %). Black: default fat blood flow (0.056 liters/
min/Kg); Red: 2 times default value.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/5
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the washout rate should also be decreased by 13% by the
artifact. Since, during washout, the inspired concentration
is zero, this means that the washout end tidal concentra-
tion should be 13% less than the arterial partial pressure.
Thus, if the artifact was symmetrical, the difference be-
tween the end tidal and arterial partial pressure during
washout should be only about 1/5 of the difference dur-
ing uptake (13% versus 55% difference). Errors of this
magnitude (13%) can be swamped by the normal varia-
tions in Kbair that result from variations in the blood fat
content.
The observant reader should, at this point, be asking why
toluene can be modeled by PKQuest (figs. 5 and 6) if it
has a similar Kbair and, therefore, similar washin-wash-
out artifact as methoxyflurane. There are 2 reasons: 1)
Only the washout data was modeled so that one would
expect only a small (13%) error; and 2) This small error in
the washout data was not present because the value of
Kbair that was used for this modeling (Table I, Pierce et al
[32]) was determined from the experimental ratios of the
blood/end tidal air for each subject, and, thus, automati-
cally compensated for this artifact. The fact that the aver-
age value of this "in vivo" Kbair was about 10% larger
than the "in vitro" value [32] is consistent with an end tid-
al partial pressure that is 10% less than the arterial partial
pressure.
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